id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0263-0004,FDA,FDA-2003-E-0263,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-23T17:30:45Z,,0,0,09000064804904a7
FDA-2003-E-0263-0003,FDA,FDA-2003-E-0263,Determination of Regulatory Review Period for Purposes of Patent Extension; ABILIFY,Notice,Determinations,2003-11-28T05:00:00Z,2003,11,2003-11-26T05:00:00Z,,2025-10-23T17:25:51Z,03-29464,0,0,09000064804904a6
FDA-2003-E-0263-0002,FDA,FDA-2003-E-0263,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-23T17:21:14Z,,0,0,09000064804904a5
FDA-2003-E-0263-0001,FDA,FDA-2003-E-0263,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-10-06T04:00:00Z,2003,10,,,2025-10-23T17:18:56Z,,0,0,09000064804904a1